A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. [electronic resource]
Producer: 20150611Description: 439-45 p. digitalISSN:- 1600-0609
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Azacitidine -- administration & dosage
- Benzoates -- administration & dosage
- Blood Platelets -- drug effects
- Cell Cycle -- drug effects
- Drug Synergism
- Drug Therapy, Combination
- Female
- Hematopoietic Stem Cells -- drug effects
- Humans
- Hydrazines -- administration & dosage
- Ischemic Attack, Transient -- etiology
- Male
- Middle Aged
- Myelodysplastic Syndromes -- complications
- Pilot Projects
- Platelet Count
- Pyrazoles -- administration & dosage
- Receptors, Thrombopoietin -- agonists
- Remission Induction
- Thrombocytopenia -- complications
- Treatment Outcome
- Venous Thrombosis -- etiology
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.